(:GNMK)

Apr 06, 2021 11:50 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MLND, KSHB, GNMK, ALXN; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Millendo Therapeutics, Inc. (NASDAQ: MLND) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Apr 01, 2021 02:23 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates TPCO, DSSI, GNMK, BMTC; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Tribune Publishing Company (NASDAQ: TPCO) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Mar 31, 2021 07:50 pm ET
GENMARK ALERT: Bragar Eagel & Squire, P.C. Investigates Recently Announced Tender Offer for GNMK and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, advises that a tender offer to acquire GenMark Diagnostics, Inc. (NASDAQ: GNMK) has commenced and reminds investors that the firm is investigating whether GenMark’s...
Mar 25, 2021 01:33 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates TPCO, STAY, GNMK, WIFI; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Tribune Publishing Company (NASDAQ: TPCO) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Mar 24, 2021 07:00 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of TPCO, FRTA, GNMK, and BMTC Buyouts
Rigrodsky Law, P.A. announces that it is investigating: Tribune Publishing Company (NASDAQ GS: TPCO) regarding possible breaches of fiduciary duties and other violations of law related to Protective Insurance’s agreement to be acquired by The...
Mar 18, 2021 11:22 am ET
STOCK ALERT: Halper Sadeh LLP Investigates RMBL, STAY, GNMK, TPCO; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: RumbleOn, Inc. (NASDAQ: RMBL) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its...
Mar 17, 2021 02:02 pm ET
GENMARK INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GenMark Diagnostics - GNMK
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of GenMark Diagnostics (NasdaqGM: GNMK) to F. Hoffmann-La Roche Ltd. Under the terms of the proposed transaction, shareholders of GenMark will receive only $24.05 in cash for each share of GenMark that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Mar 15, 2021 06:36 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of GenMark Diagnostics, Inc. Buyout
Rigrodsky Law, P.A. announces that it is investigating GenMark Diagnostics, Inc. (“GenMark”) (NASDAQ GM: GNMK) regarding possible breaches of fiduciary duties and other violations of law related to GenMark’s agreement to be acquired by Roche...
Mar 15, 2021 02:21 pm ET
GENMARK DIAGNOSTICS INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating the GenMark Diagnostics acquisition by F. Hoffman La-Roche Ltd.
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating GenMark Diagnostics (“GenMark”) (NASDAQ: GNMK) regarding possible breaches of fiduciary duties and other violations of law related to GenMark’s agreement to be acquired by...
Mar 15, 2021 01:57 pm ET
GENMARK ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of GNMK and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of GenMark Diagnostics, Inc. (NASDAQ: GNMK) breached their fiduciary duties or violated the federal...
Mar 15, 2021 11:24 am ET
GenMark Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of GenMark Diagnostics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GNMK
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of GenMark Diagnostics, Inc. (NASDAQ: GNMK) to Roche is fair to GenMark shareholders. Under the terms of the merger agreement, Roche will acquire all outstanding shares of GenMark common stock for $24.05 per share in cash.
Feb 25, 2021 04:05 pm ET
GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results
GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fiscal year and quarter ended December 31, 2020. Full Year...
Feb 22, 2021 04:05 pm ET
GenMark ePlex® RP2 Panel Predicted to Detect Known SARS-CoV-2 Variants Currently in Circulation Based on in silico Analysis
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 (RP2) is predicted to detect known SARS-CoV-2 variants currently...
Feb 16, 2021 05:34 pm ET
GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference
GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health...
Feb 16, 2021 04:03 pm ET
Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today the publication of a manuscript in Frontiers in Cellular and Infection Microbiology that highlights strong...
Feb 11, 2021 04:17 pm ET
GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review the company's...
Jan 11, 2021 04:08 pm ET
GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2020. Financial Highlights...
Dec 28, 2020 04:05 pm ET
GenMark Diagnostics to Participate in Upcoming Investor Conferences
GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences....
Nov 05, 2020 04:05 pm ET
GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum
GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Virtual MedTech...
Oct 28, 2020 04:05 pm ET
GenMark Diagnostics Reports Third Quarter 2020 Results
GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended September 30, 2020. Third Quarter 2020 Highlights Total revenue of...
Oct 14, 2020 05:20 pm ET
GenMark Diagnostics to Report Third Quarter 2020 Financial Results on October 28, 2020
GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on Wednesday, October 28, 2020. Management will hold a conference call to review the company's financial...
Oct 08, 2020 04:05 pm ET
GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) Receives EUA from FDA
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its ePlex® Respiratory Pathogen...
Oct 08, 2020 04:03 pm ET
GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary financial results for the quarter ended September 30, 2020. Third Quarter 2020 Highlights Placed...
Sep 22, 2020 07:00 am ET
Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments
MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Lisa Giles and Robert Wills to its Board of Directors, effective October 1, 2020. Ms. Giles will serve as a member of the Audit Committee of the Board and Dr. Wills will serve as a member of the Nominating & Corporate Governance Committee of the Board. 
Sep 14, 2020 04:05 pm ET
GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) achieves CE Mark
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has achieved CE Mark under the European In‐Vitro Diagnostic Devices Directive (98/79/EC) for its...
Aug 17, 2020 08:00 am ET
GenMark Diagnostics Announces Submission of Emergency Use Authorization for its eSensor® SARS-CoV-2 Test
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced that it has notified the U.S. Food and Drug Administration (FDA) of the intent to commercially distribute the...
Aug 04, 2020 04:05 pm ET
GenMark Diagnostics Reports Second Quarter 2020 Results
GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2020. Second Quarter 2020 Highlights Total revenue of...
Jul 29, 2020 04:05 pm ET
GenMark Diagnostics to Participate in Upcoming Investor Conferences
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences. GenMark’s management team is...
Jul 21, 2020 04:05 pm ET
GenMark Diagnostics to Report Second Quarter 2020 Financial Results on August 4, 2020
GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its second quarter earnings results after market close on Tuesday, August 4, 2020. Management will hold a conference call to review the company's financial...
Jul 07, 2020 04:05 pm ET
GenMark Diagnostics Provides Preliminary Financial and Operational Results for Second Quarter 2020
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary financial and operational results for the quarter ended June 30, 2020. Second Quarter 2020...
Jun 29, 2020 07:00 am ET
GenMark Diagnostics Announces Commercial Launch of its ePlex® Respiratory Pathogen Panel 2 (RP2)
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced that its ePlex® Respiratory Pathogen 2 (RP2) Panel is now available for U.S. commercial distribution and clinical...
Jun 16, 2020 08:00 am ET
GenMark Diagnostics Chosen as Primary Provider of Rapid Diagnostic Testing for Vidant Health
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, has been selected by Vidant Health as its primary provider of rapid diagnostic testing. Vidant is deploying GenMark’s ePlex®...
May 27, 2020 04:05 pm ET
GenMark Diagnostics to Participate in Upcoming Investor Conferences
GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics,...
May 11, 2020 04:01 pm ET
GenMark Diagnostics Announces Closing of $80 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics,...
May 07, 2020 09:31 am ET
Thinking about buying stock in GenMark Diagnostics, BioSig Technologies, Norwegian Cruise Line, J C Penney, or Delphi Technologies?
NEW YORK, May 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNMK, BSGM, NCLH, JCP, and DLPH.
May 06, 2020 10:59 pm ET
GenMark Prices Public Offering of Common Stock
GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics,...
May 06, 2020 04:01 pm ET
GenMark Commences Public Offering of Common Stock
GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics,...
May 04, 2020 04:05 pm ET
GenMark Diagnostics Reports First Quarter 2020 Results
GenMark Diagnostics, Inc. ("GenMark" or the "Company") (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended March 31, 2020. First Quarter 2020...
May 04, 2020 04:03 pm ET
GenMark Diagnostics Announces Scott Mendel Appointed CEO
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel has been appointed President and Chief Executive Officer effective immediately. Mendel, who...
Apr 22, 2020 04:05 pm ET
GenMark Diagnostics to Report First Quarter 2020 Financial Results on May 4, 2020
GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its first quarter earnings results after market close on Monday, May 4, 2020. Management will hold a conference call to review the company's financial performance...
Apr 07, 2020 04:03 pm ET
GenMark Diagnostics Provides Preliminary Financial and Operational Results for First Quarter 2020 and Increases 2020 Revenue Guidance
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary financial and operational results for the quarter ended March 31, 2020 and increased its full year...
Mar 23, 2020 07:45 pm ET
GenMark Awarded BARDA Grant for the Development of ePlex® RP2 Panel
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has been awarded a grant from the Biomedical Advanced Research and Development Authority (BARDA), part of...
Mar 20, 2020 09:31 am ET
Thinking about buying stock in EXACT Sciences, GenMark Diagnostics, SunLink Health Systems, Tyson Foods, or Slack Technologies?
NEW YORK, March 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXAS, GNMK, SSY, TSN, and WORK.
Mar 19, 2020 09:23 pm ET
GenMark Receives FDA Emergency Use Authorization for its ePlex® SARS-CoV-2 Test
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the...
Mar 11, 2020 08:00 am ET
GenMark Diagnostics Announces Submission of Emergency Use Authorization for its ePlex® SARS-CoV-2 Test
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced submission for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its...
Mar 02, 2020 04:05 pm ET
GenMark Diagnostics Reports Fourth Quarter and Full Year 2019 Results
GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2019. Full Year 2019 Financial...
Mar 02, 2020 04:03 pm ET
GenMark Diagnostics Announces Global Shipments of ePlex® RUO Test Kits Designed for SARS-CoV-2 Detection
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the initial shipments of ePlex Research Use Only (RUO) test kits designed to detect the SARS-CoV-2 virus....
Feb 18, 2020 04:05 pm ET
GenMark Diagnostics to Participate in the Cowen Health Care Conference
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen Health Care Conference in Boston, Massachusetts....
Feb 10, 2020 05:30 pm ET
GenMark Diagnostics Schedules Fourth Quarter and Full Year 2019 Financial Results Conference Call for March 2, 2020
GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Monday, March 2, 2020. Management will hold a conference call to review the company's...
Feb 10, 2020 05:15 pm ET
GenMark Diagnostics Announces CEO and Chairman Transition
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel, Chief Operating Officer, has been appointed Interim President and Chief Executive Officer...
Jan 13, 2020 07:00 am ET
GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2019
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2019. Financial Highlights...
Dec 30, 2019 04:05 pm ET
GenMark Diagnostics to Participate in the J.P. Morgan Healthcare Conference
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming J.P. Morgan Healthcare conference in San Francisco,...
Nov 13, 2019 04:05 pm ET
GenMark Diagnostics to Participate in Upcoming Investor Conferences
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences. GenMark’s management is scheduled...
Nov 06, 2019 04:03 pm ET
GenMark Diagnostics Reports Third Quarter 2019 Results
GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended September 30, 2019. Highlights Recognized total revenue of...
Oct 23, 2019 04:05 pm ET
GenMark Diagnostics Schedules Third Quarter 2019 Financial Results Conference Call for November 6, 2019
GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on Wednesday, November 6, 2019. Management will hold a conference call to review the company's financial...
Aug 05, 2019 04:05 pm ET
GenMark Diagnostics Reports Second Quarter 2019 Results
GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2019. Highlights Recognized total revenue of $18.4...
Jul 25, 2019 04:05 pm ET
GenMark Diagnostics to Participate in the Canaccord Genuity Growth Conference
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Genuity Growth Conference in Boston, MA....
Jul 22, 2019 04:05 pm ET
GenMark Diagnostics Schedules Second Quarter 2019 Financial Results Conference Call for August 5, 2019
GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its second quarter earnings results after market close on Monday, August 5, 2019. Management will hold a conference call to review the company's financial performance...
May 23, 2019 04:05 pm ET
GenMark Diagnostics to Participate in Upcoming Investor Conferences
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in three upcoming investor conferences. GenMark’s management team will...
May 01, 2019 04:05 pm ET
GenMark Diagnostics to Present at the Bank of America Merrill Lynch Health Care Conference
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the Bank of America Merrill Lynch Heath Care Conference in Las...
Apr 30, 2019 04:05 pm ET
GenMark Diagnostics Reports First Quarter 2019 Results
GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended March 31, 2019. Highlights Recognized total revenue of $21.5...
Apr 30, 2019 04:02 pm ET
GenMark Diagnostics Expands Commercial Team
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has expanded its commercial team in North America with the addition of Michael Harkins as Senior Vice...
Apr 15, 2019 07:45 am ET
GenMark Diagnostics Schedules First Quarter 2019 Financial Results Conference Call for April 30, 2019
GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, April 30, 2019. Management will hold a conference call to review the company's financial performance...
Apr 15, 2019 07:30 am ET
GenMark Diagnostics Receives FDA 510(k) Market Clearance for its ePlex Blood Culture Identification Gram-Negative Panel
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has received FDA 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for its...
Apr 12, 2019 07:25 am ET
Market Trends Toward New Normal in ZTO Express (Cayman), ProPetro Holding, Social Reality, The Habit Restaurants, GenMark Diagnostics, and Power Integrations — Emerging Consolidated Expectations, Anal
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ZTO Express (Cayman) Inc. (NYSE:ZTO), ProPetro Holding Corp. (NYSE:PUMP),...
Feb 21, 2019 04:05 pm ET
GenMark Diagnostics Reports Fourth Quarter and Full Year 2018 Results
GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2018. Financial Highlights...
Feb 21, 2019 04:03 pm ET
GenMark Diagnostics Announces Expansion of Executive Leadership Team
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the expansion of its executive leadership team. Effective immediately, Scott Mendel, currently GenMark's Chief...
Feb 20, 2019 04:55 pm ET
GenMark Diagnostics to Participate in Upcoming Investor Conferences
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences. GenMark’s management team will be...
Feb 07, 2019 04:43 pm ET
GenMark Diagnostics Schedules Fourth Quarter and Full Year 2018 Financial Results Conference Call for February 21, 2019
GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter earnings results after market close on Thursday, February 21, 2019. Management will hold a conference call to review the Company's financial...
Jan 30, 2019 07:25 am ET
New Research Coverage Highlights Cummins, R.R. Donnelley & Sons, James River Group, HNI, GenMark Diagnostics, and EP Energy — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cummins Inc. (NYSE:CMI), R.R. Donnelley & Sons Company (NYSE:RRD), James...
Jan 08, 2019 08:00 am ET
GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2018
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2018. Financial Highlights...
Dec 26, 2018 08:00 am ET
GenMark Diagnostics Receives FDA 510(k) Market Clearance for its ePlex Blood Culture Identification Fungal Pathogen Panel
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has received FDA 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for its...
Dec 20, 2018 02:15 pm ET
GenMark Diagnostics Receives FDA 510(k) Market Clearance for its ePlex Blood Culture Identification Gram-Positive Panel
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has received FDA 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for its...
Dec 19, 2018 05:22 pm ET
GenMark Diagnostics to Present at the J.P. Morgan Healthcare Conference
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the Company plans to participate in the J.P. Morgan Healthcare Conference in San Francisco, CA....
Nov 07, 2018 04:05 pm ET
GenMark Diagnostics to Present at Upcoming Investor Conferences
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the company plans to participate in two upcoming investor conferences. GenMark’s management is scheduled to...
Nov 06, 2018 07:50 am ET
Analysis: Positioning to Benefit within Hess Midstream Partners LP, Quanta Services, ServiceSource International, Meritor, Donegal Group, and GenMark Diagnostics — Research Highlights Growth, Revenue,
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hess Midstream Partners LP (NYSE:HESM), Quanta Services, Inc. (NYSE:PWR),...
Oct 29, 2018 04:05 pm ET
GenMark Diagnostics Reports Third Quarter 2018 Results
GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the third quarter ended September 30, 2018. Highlights Recognized revenues of...
Oct 15, 2018 04:05 pm ET
GenMark Diagnostics Schedules Third Quarter Financial Results Conference Call for October 29, 2018
GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on Monday, October 29, 2018. Management will hold a conference call to review the Company's financial...
Oct 15, 2018 09:25 am ET
Analysis: Positioning to Benefit within PTC, H&R Block, GenMark Diagnostics, American International Group, Newmont Mining, and Stryker — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of PTC Inc. (NASDAQ:PTC), H Block, Inc. (NYSE:HRB), GenMark Diagnostics,...
Oct 02, 2018 04:14 pm ET
GenMark Diagnostics Announces FDA Submission of its ePlex Blood Culture Identification Gram-Negative and ePlex Blood Culture Identification Fungal Pathogen Panels
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the submission of two additional ePlex Blood Culture Identification Panels – the Gram-Negative (BCID-GN) Panel...
Aug 13, 2018 08:30 am ET
Recent Analysis Shows SUPERVALU INC, GenMark Diagnostics, E.W. Scripps, Cooper Tire & Rubber, Nexstar Broadcasting Group, and Cloud Peak Energy Market Influences — Renewed Outlook, Key Drivers of Grow
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SUPERVALU INC. (NYSE:SVU), GenMark Diagnostics, Inc. (NASDAQ:GNMK), E.W....
Jul 30, 2018 04:05 pm ET
GenMark Diagnostics Reports Second Quarter 2018 Results
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2018. Highlights Recognized revenues of $14.9...
Jul 25, 2018 04:03 pm ET
GenMark Diagnostics to Present at the Canaccord Genuity 38th Annual Growth Conference
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany, will participate in the Canaccord Genuity 38th...
Jul 16, 2018 05:31 pm ET
GenMark Diagnostics Schedules Second Quarter Financial Results Conference Call for July 30, 2018
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Monday, July 30, 2018. Management will hold a conference call to review the Company's financial performance...
Jun 28, 2018 04:57 pm ET
GenMark Diagnostics Announces FDA Submission of its ePlex Blood Culture Identification Gram Positive Panel
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced submission of its ePlex Blood Culture ID – Gram Positive (BCID-GP) panel to the U.S. Food and Drug...
Jun 06, 2018 08:00 am ET
GenMark Diagnostics to Present at the William Blair 38th Annual Growth Stock Conference
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany, will present at the William Blair 38th Annual...
May 14, 2018 08:15 am ET
Analysis: Positioning to Benefit within Cirrus Logic, Aaron's, Waste Connections, Shake Shack, R.R. Donnelley & Sons, and GenMark Diagnostics — Research Highlights Growth, Revenue, and Consolidated Re
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cirrus Logic, Inc. (NASDAQ:CRUS), Aaron's, Inc. (NYSE:AAN), Waste...
May 02, 2018 04:03 pm ET
GenMark Diagnostics to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
CARLSBAD, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany, will present at the Bank of...
May 01, 2018 04:05 pm ET
GenMark Diagnostics Reports First Quarter 2018 Results
CARLSBAD, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2018.
Apr 17, 2018 04:03 pm ET
GenMark Diagnostics Schedules First Quarter Financial Results Conference Call for May 1, 2018
CARLSBAD, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 1, 2018. Management will hold a conference call to...
Feb 27, 2018 04:03 pm ET
GenMark Diagnostics Reports Fourth Quarter and Full Year 2017 Results
CARLSBAD, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and full year ended December 31, 2017.
Feb 27, 2018 12:40 pm ET
GenMark Diagnostics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / GenMark Diagnostics, Inc. (NASDAQ: GNMK) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 4:30 PM Eastern Time.
Feb 21, 2018 04:03 pm ET
GenMark Diagnostics to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that the Company plans to participate in two upcoming investor conferences.
Feb 13, 2018 04:03 pm ET
GenMark Diagnostics Schedules Fourth Quarter and Full Year 2017 Financial Results Conference Call for February 27, 2018
CARLSBAD, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its fourth quarter earnings results after market close on Tuesday, February 27, 2018. Management will hold a conference call to...
Feb 12, 2018 08:00 am ET
Research Report Identifies Waste Connections, Hercules Capital, Crown, GenMark Diagnostics, Clorox, and Cavium with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 12, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Waste Connections, Inc. (NYSE:WCN), Hercules Capital,...
Jan 09, 2018 07:05 am ET
GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2017
CARLSBAD, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2017.
Dec 21, 2017 04:03 pm ET
GenMark Diagnostics to Present at the J.P. Morgan 36th Annual Healthcare Conference
CARLSBAD, Calif., Dec. 21, 2017 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany, will present at the J.P. Morgan...
Nov 21, 2017 08:30 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Waste Connections, Hercules Capital, Scientific Games, GenMark Diagnostics, Clorox, and Cavium — New Research Emphasizes Economic Gr
NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Waste Connections, Inc. (NYSE:WCN), Hercules Capital,...
Nov 14, 2017 03:07 pm ET
GNMK INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of GenMark Diagnostics, Inc. Investors
Law Offices of Howard G. Smith continues its investigation on behalf of GenMark Diagnostics, Inc. (“GenMark” or the “Company”) (NASDAQ: GNMK) investors concerning the Company and its officers’ possible violations of federal securities laws.
Nov 11, 2017 07:19 pm ET
ACT NOW: Monteverde & Associates PC Announces an Investigation of GenMark Diagnostics, Inc. - GNMK
NEW YORK, Nov. 11, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City announces an investigation against GenMark Diagnostics, Inc. (NasdaqGM: GNMK)("GenMark" or the "Company") for possible violations of federal securities laws.
Nov 10, 2017 01:30 pm ET
Glancy Prongay & Murray LLP Continues Investigation on Behalf of GenMark Diagnostics, Inc. Investors (GNMK)
Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of GenMark Diagnostics, Inc. (“GenMark” or the “Company”) (NASDAQ:
Nov 08, 2017 07:30 am ET
GNMK INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of GenMark Diagnostics, Inc. Investors
Law Offices of Howard G. Smith announces an investigation on behalf of GenMark Diagnostics, Inc. (“GenMark” or the “Company”) (NASDAQ: GNMK) investors concerning the Company and its officers’ possible violations of federal securities laws.
Nov 07, 2017 09:30 pm ET
GenMark Diagnostics to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum in New York, NY.
Nov 03, 2017 05:29 pm ET
Glancy Prongay & Murray LLP Commences Investigation on Behalf of GenMark Diagnostics, Inc. Investors (GNMK)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of GenMark Diagnostics, Inc. (“GenMark” or the “Company”) (NASDAQ:
Nov 03, 2017 04:27 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GenMark Diagnostic, Inc. - GNMK
NEW YORK, Nov. 3, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GenMark Diagnostic, Inc. ("GenMark" or the "Company") (NASDAQ: GNMK).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Nov 03, 2017 02:55 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of GenMark Diagnostics, Inc. (GNMK)
NEW YORK, Nov. 3, 2017 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GenMark Diagnostics, Inc. ("GenMark" or the "Company") (NASDAQ: GNMK). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/gnmk.
Nov 03, 2017 12:39 pm ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against GenMark Diagnostics, Inc. – GNMK
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of GenMark Diagnostics, Inc. (NASDAQ:GNMK) resulting from allegations that GenMark may have issued materially misleading business information to the investing public.
Nov 02, 2017 04:05 pm ET
GenMark Diagnostics Reports Third Quarter 2017 Results
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the third quarter ended September 30, 2017.
Oct 19, 2017 03:47 pm ET
GenMark Diagnostics Schedules Third Quarter 2017 Financial Results Conference Call for November 2, 2017
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Thursday, November 2, 2017. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.